New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase

Current Topics in Medicinal Chemistry

Volumn 6, Issue 2, 2006, Pages 113-149

  Peifer, Christian ^c   Wagner, Gerd ^b   Laufer, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c NONE

Author keywords

Anilinoquinazoline; Crystallisation; Cytokine; Fused heterocycles; N Substituted imidazoles; TNF alpha release

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (3 MORPHOLINOPROPYL)IMIDAZOLE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ADALIMUMAB; ETANERCEPT; IMIDAZOLE DERIVATIVE; INFLIXIMAB; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RP 66425; RPR 132331; RPR 201227A; RPR 203494; SB 206718; SB 216385; SB 216995; SB 218655; SB 226882; SB 242235; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL ACTIVITY; CHRONIC INFLAMMATION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG TARGETING; ENTERITIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MOLECULAR DYNAMICS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; VALIDATION STUDY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646165882     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606775270323     Document Type: Review

References (93)

1. Braddock, M.; Quinn, A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 2004, 3, 330-340.
2. Taylor, P.C. Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern. Med. 2003, 42, 15-20.
3. Palladino, M.A.; Bahjat, F.R.; Theodorakis, E.A.; Moldawer, L.L. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov. 2003, 2, 736-746.
4. Choy, E.H.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344, 907-916.
5. Lee, J.C.; Laydon, J.T.; McDonnell, P.C.; Gallagher, T.F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M.J.; Heyes, J.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nat. (London) 1994, 372, 739-746.
6. Kumar, S.; Boehm, J.; Lee, J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2003, 2, 717-726.
7. Lantos, I.; Bender, P.E.; Razgaitis, K.A.; Sutton, B.M.; DiMartino, M.J.; Griswold, D.E.; Walz, D.T. Antiinflammatory activity of 5,6-diaryl-2,3-dihydroimidazo[2,1-#1b]thiazoles. Isomeric 4-pyridyl and 4-substituted phenyl derivatives. J. Med. Chem. 1984, 27, 72-75.
8. Lee, J.C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, JL. p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol. Therap. 1999, 82, 389-397.
9. Boehm, J.C.; Adams, J.L. New inhibitors of p38 kinase. Exp. Opin. Therapeut. Pat. 2000, 10, 25-37.
10. Foster, M.L.; Halley, F.; Souness, J.E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. 2000, 13, 488-497.
11. Lee, J.C.; Kumar, S.; Griswold, D.E.; Underwood, D.C.; Votta, B.J.; Adams, J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacol. 2000, 47, 185-201.
12. Jackson, P.F.; Bullington, J.L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. (Hilversum, Netherlands) 2002, 2, 1011-1020.
13. Black, R.A.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.; Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K-A.; Gerhart, M.; Davis, R.; Fitzner, J.N.; Johnson, R.S.; Paxton, R.J.; March, C.J.; Cerretti, D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor- alpha from cells. Nature 1997, 385, 729-33.
14. Moss, M.L.; Jin, S.L; Milla, M.E.; Bickett, D.M.; Burkhart, W.; Carter, H.L.; Chen, W.J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; Hoffman, C.R.; Kost, T.A.; Lambert, M.H.; Leesnitzer, M.A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L.K.; Schoenen, F.; Seaton, T.; Su, J.L.; Becherer, J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385, 733-736.
15. Thornberry, N.A.; Bull, H.G.; Calaycay, J.R.; Chapman, K.T.; Howard, A.D.; Kostura, M.J.; Miller, D.K.; Molineaux, S.M.; Weidner, J.R.; Aunins, J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992, 356, 768-774.
16. Tong, L.; Pav, S.; White, D.M.; Rogers, S.; Crane, K.M,; Cywin, C.L.; Brown, M.L.; Pargellis, C.A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 1997, 4, 311-316.
17. Wilson, K.P.; McCaffrey, P.G.; Hsiao, K.; Pazhinisamy, S.; Galullo, V.; Bemis, G.W.; Fitzgibbon, M.J.; Caron, P.R.; Murcko, M.A.; Su, M.S.S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
18. Wang, Z.; Canagarajah, B.J.; Boehm, J.C.; Kassisa, S.; Cobb, M.H.; Young, P.R.; Abdel-Meguid, S.; Adams, J.L.; Goldsmith, E.J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
19. Gum, R.J.; Mclaughlin, M.M.; Kumar, S.; Wang, Z.; Bower, M.J.; Lee, J.C.; Adams, J.L.; Livi, G.P.; Goldsmith, E.J.; Young, P.R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 1998, 273, 15605-15610.
20. Lisnock, J.; Tebben, A.; Frantz, B.; O'Neill, E.A.; Croft, G.; O'Keefe, S.J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 1998, 37, 16573-16581.
21. Young, P.R.; McLaughlin, M.M.; Kumar, S.; Kassis, S.; Doyle, M.L.; McNulty, D.; Gallagher, T.F.; Fisher, S.; McDonnell, P.C.; Carr, S.A.; Huddleston, M.J.; Seibel, G.; Porter, T.G.; Livi, G.P.; Adams, J.L.; Lee, J.C. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 1997, 272, 12116-12121.
22. Adams, J.L.; Boehm, J.C.; Kassis, S.; Gorycki, P.D.; Webb, E.F.; Hall, R.; Sorenson, M.; Lee, J.C.; Ayrton, A.; Griswold, D.E.; Gallagher, T.F. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. 1998, 8, 3111-3116.
23. Liverton, N.J.; Butcher, J.W.; Claiborne, C.F. Claremon, D.A.; Libby, B.E.; Nguyen, K.T.; Pitzenberger, S.M.; Selnick, H.G.; Smith, G.R.; Tebben, A.; Vacca, J.P.; Varga, S.L.; Agarwal, L.; Dancheck, K.; Forsyth, A.J.; Fletcher, D.S.; Frantz, B.; Hanlon, W.A.; Harper, C.F.; Hofsess, S.J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E.A.; Orevillo, C.J.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Visco, D.M.; O'Keefe, S.J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 1999, 42, 2180-2190.
24. Laufer, S.A.; Wagner, G.K.; Kotschenreuther, D.A.; Albrecht, W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J. Med. Chem. 2003, 46, 3230-3244.
25. Gallagher, T.F.; Fier-Thompson, S.M.; Garigipati, R.S.; Sorenson, M.E.; Smietana, J.M.; Lee, D.; Bender, P.E.; Lee, J.C.; Laydon, J.T. 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Med. Chem. Lett. 1995, 5, 1171-1176.
26. Boehm, J.C.; Smietana, J.M.; Sorenson, M.E.; Garigipati, R.S.; Gallagher, T.F.; Sheldrake, P.L.; Bradbeer, J.; Badger, A.M.; Laydon, J.T.; Lee, J.C.; Hillegass, L.M.; Griswold, D.E.; Breton, J.J.; Chabot-Fletcher, M.C.; Adams, J.L. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem. 1996, 39, 3929-3937.
27. Gallagher, T.F.; Seibel, G.L.; Kassis, S.; Laydon, J.T.; Blumenthal, M.J.; Lee, J.C.; Lee, D.; Boehm, J.C.; Fier-Thompson, S.M.; Abt, J.W.; Soreson, M.E.; Smietana, J.M.; Hall, R.F.; Garigipati, R.S.; Bender, P.E.; Erhard, K.F.; Krog, A.J.; Hofmann, G.A.; Sheldrake, P.L.; McDonnell, P.C.; Kumar, S.; Young, P.R.; Adams, J.L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem, 1997, 5, 49-64.
28. Revesz, L,; Di Padova, F.E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Wolf, R.; Zimmerlin, A.G. SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 2109-2112.
29. Adams, J.L.; Boehm, J.C.; Hall, R.F.; Taggart, J.J. Preparation of 1,5-disubstituted-3,4-dihydro-1H-pyrimido[4,5-d]pyrimidin-2-ones for treatment of CSBP/p38 kinase mediated diseases. Edited by Smithkline Beecham Corp. 2001-US6688[0164679], 102. 2001. WO. Ref Type: Patent
30. Manthey, C.L.; Wang, S.W.; Kinney, S.D.; Yao, Z. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J. Leukoc. Biol. 1998, 64, 409-417.
31. Mclay, L.M.; Halley, F.; Souness, J.E.; McKenna, J.; Benning, V.; Birrell, M.; Burton, B.; Belvisi, M.; Collis, A.; Constan, A.; Foster, M.; Hele, D.; Jayyosi, Z.; Kelley, M.; Maslen, C.; Miller, G.; Ouldelhkim, M.C.; Page, K.; Phipps, S.; Pollock, K.; Porter, B.; Ratcliffe, A.J.; Redford, E.J.; Webber, S.; Slater, B.; Thybaud, V.; Wilsher, N. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg. Med. Chem. 2000, 9, 537-554.
32. Collis, A.J.; Foster, M.L.; Halley, F.; Maslen, C.; McLay, I.M.; Page, K.M.; Redford, E.J.; Souness, J.E.; Wilsher, N.E. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. Bioorg. Med. Chem. Lett. 2001, 11, 693-696.
33. Revesz, L.; Di Padova, F.E.; Buhl, T.; Feifel, R; Gram, H.; Hiestand, P.; Manning, U.; Zimmerlin, A.G. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 1261-1264.
34. Fitzi, K. 4(5)-Aryl-5(4)-pyridylimidazoles. Edited by (Ciba-Geigy A.-G.). 72-2221546[2221546], 57. 1972. DE. 3-5-1972. RefType: Patent
35. Lee, J.C.; Badger, A.M.; Griswold, D.E.; Dunnington, D.; Truneh, A.; Votta, B.; White, J.R.; Young, P.R.; Bender, P.E. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann. NY Acad. Sci. 1993, 696, 149-170.
36. Adams, J.L.; Boehm, J.C.; Gallagher, T.F.; Kassis, S.; Webb, E.F.; Hal, R.; Sorenson, M.; Garigipati, R.; Griswold, D.E.; Lee, J.C. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg. Med. Chem. Lett. 2001, 11, 2867-2870.
37. Adams, J.L.; Boehm, J.C.; Gallagher, T.F.; Kassis, S.; Webb, E.F.; Hall, R.; Sorenson, M.; Garigipati, R.; Griswold, D.E.; Lee, J.C. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg. Med. Chem. Lett. 2001, 11, 2867-2870.
38. Boehm, J.C.; Bower; M.J.; Gallagher, T.F.; Kassis, S.; Johnson, S.R.; Adams, J.L. Phenoxypyrimidine inhibitors of p38.alpha. kinase synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles. Bioorg. Med. Chem. Lett. 2001, 11, 1123-1126.
39. Underwood, D.C.; Osborn, R.R.; Bochnowicz, S.; Webb, E.F.; Rieman, D.J.; Lee, J.C.; Romanic, A.M; Adams, J.L.; Hay, D.W.; Griswold, D.E. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, 895-902.
40. Underwood, D.C.; Osborn, R.R.; Kotzer, C.J.; Adams, J.L.; Lee, J.C.; Webb, E.F.; Carpenter, D.C.; Bochnowicz, S.; Thomas, H.C.; Hay, D.W.; Griswold, D.E. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. PharmacoL Exp. Ther. 2000, 293, 281-288.
41. Badger, A.M.; Griswold, D.E.; Kapadia, R.; Blake, S.; Swift, B.A.; Hoffman, S.J.; Stroup, G.B.; Webb, E.; Rieman, D.J.; Gowen, M.; Boehm, J.C.; Adams, J.L.; Lee, J.C. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 2000, 43, 175-183.
42. Fullerton, T.; Sharma, A.; Prabhakar, U.; Tucci, M.; Boike, S.; Davis, H.; Jorkasky, D.; Williams, W. Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 map kinase. Clin. Pharmacol. Therap. 2000, 67, 114.
43. Underwood, D.C.; Osborn, R.R.; Kotzer, C.J.; Adams, J.L.; Lee, J.C.; Webb, E.F.; Carpenter, D.C.; Bochnowicz, S.; Thomas, H.C.; Hay, D.W.P.; Griswold, D.E. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J. Pharmacol. Exp. Therap. 2000, 293, 281-288.
44. LoGrasso, P.V.; Frantz, B.; Rolando, A.M.; O'Keefe, S.J.; Hermes, J.D.; O'Neill, E.A. Kinetic mechanism for p38 MAP kinase. Biochemistry 1997, 36, 10422-10427.
45. Frantz, B.; Klatt T.; Pang, M.; Parsons, J.; Rolando, A.; Williams, H.; Tocci, M.J.; O'Keefe, S.J.; O'Neill, E.A. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998, 37, 13846-13853.
46. Thurmond, R.L.; Wadsworth, S.A.; Schafer, P.H.; Zivin, R.A.; Siekierka, J.J. Kinetics of small molecule inhibitor binding to p38 kinase. Eur. J. Biochem. 2001, 268, 5747-5754.
47. Wadsworth, S.A.; Cavender, D.E.; Beers, S.A.; Lalan, P; Schafer, P.H.; Malloy, E.A.; Wu, W.; Fahmy, B.; Olini, G.C.; Davis, J.E.; Pellegrino-Gensey, J.L.; Wachter, M.P.; Siekierka, J.J. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol Exp. Ther. 1999, 291, 680-687.
48. Revesz, L.; Blum, E; Di Padova, F.E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Rucklin, G. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 2004, 14, 3595-3599.
49. Laufer, S.A.; Striegel, H.; Wagner, G.K. Imidazole inhibitors of cytokine release: probing substituents in the 2 position. J. Med. Chem. 2002, 45, 4695-4705.
50. Laufer, S.; Striegel, H-G.; Neher, K. Preparation of 2-aralkylthioimidazoles and related compounds as antiinflammatories. Edited by (Merckle G.m.b.H. G. [0017192], 53. 2000. WO. RefType: Patent
51. Wachter, M. Preparation of 2-substituted imidazoles useful in the treatment of inflammatory diseases. Edited by (Orto-McNeil Pharmaceutical IU. 98-US13419 [9903837], 55. 1999. WO. 29-6-1998. RefType: Patent
52. Laufer, S.; Wagner, G.; Kotschenreuther, D. Ones, Thiones and N-Oxides: An exercise in imidazole chemistry. Ang. Chem. Inter. Ed. 2002, im Druck.
53. de Laszlo, S.E.; Visco, D.; Agarwal, L.; Chang, L.; Chin, J.; Croft, G.; Forsyth, A.; Fletcher, D.; Frantz, B.; Hacker, C.; Hanlon, W.; Harper, C.; Kostura, M.; Li, B.; Luell, S.; MacCoss, M.; Mantlo, N.; O'Neill, E.A.; Orevillo, C.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Sidler, K.; O'Keefe, S.J. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. 1998, 8, 2689-2694.
54. Tullis, J.S.; VanRens, J.C.; Natchus, M.G.; Clark, M.P.; De, B.; Hsieh, L.C.; Janusz, M.J. The development of new triazole based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production. Bioorg. Med. Chem. Lett. 2003, 13, 1665-1668.
55. Fujita, M.; Seki, T.; Ikeda, N. Synthesis and bioactivities of novel bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production. Bioorg. Med. Chem. Lett. 2002, 12, 1897-1900.
56. Fujita, M.; Seki, T.; Ikeda, N. Synthesis and bioactivities of novel bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production. Bioorg. Med. Chem. Lett. 2002, 12, 1897-1900.
57. Laufer, S.A.; Wagner, G.K. From imidazoles to pyrimidines: new inhibitors of cytokine release. J. Med. Chem. 2002, 45, 2733-2740.
58. McIntyre, C.J.; Ponticello, G.S.; Liverton, N.J.; O'Keefe, S.J.; O'Neill, E.A.; Pang, M.; Schwartz, C.D.; Claremon, D.A. Pyridazine based inhibitors of p38 MAPK. Bioorg. Med. Chem. Lett. 2002, 12, 689-692.
59. Henry, J.R.; Rupert K.C.; Dodd, J.H.; Turchi, I.J.; Wadsworth, S.A.; Cavender, D.E.; Schafer, P.H.; Siekierka, J.J. Potent inhibitors of the MAP kinase p38. Bioorg. Med. Chem. Lett. 1998, 8, 3335-3340.
60. Henry, J.R.; Rupert, K.C.; Dodd, J.H.; Turchi, I.J.; Wadsworth, S.A.; Cavender, D.E.; Fahmy, B.; Olini, G.C.; Davis, J.E.; Pellegrino-Gensey, J.L.; Schafer, P.H.; Siekierka, J.J. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A Potent and Selective p38 Kinase Inhibitor. J. Med. Chem. 1998, 41, 4196-4198.
61. Rupert, K.C.; Henry, J.R.; Dodd, J.H.; Wadsworth, S.A.; Cavender, D.E.; Olini, G.C.; Fahmy, B.; Siekierka, J.J. Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2003, 13, 347-350.
62. Clark, M.P.; Laughlin, S.K.; Laufersweiler, M.J.; Bookland, R.G.; Brugel,T.A.; Golebiowski, A.; Sabat, M.P.; Townes, J.A.; VanRens, J.C.; Djung, J.F.; Natchus, M.G.; De, B.; Hsieh, L.C.; Xu, S.C.; Walter, R.L.; Mekel, M.J.; Heitmeyer, S.A.; Brown, K.K.; Juergens, K.; Taiwo, Y.O.; Janusz, M.J. Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production. J. Med. Chem. 2004, 47, 2724-2727.
63. Trejo, A.; Arzeno, H.; Browner, M.; Chanda, S.; Cheng, S.; Comer, D.D.; Dalrymple, S.A.; Dunten, P.; Lafargue, J.; Lovejoy, B.; Freire-Moar, J.; Lim, J.; McIntosh, J.; Miller, J.; Papp, E.; Reuter, D.; Roberts, R.; Sanpablo, F.; Saunders, J.; Song, K.; Villasenor, A.; Warren, S.D.; Welch, M.; Weller, P.; Whiteley, P.E.; Zeng, L.; Goldstein,D.M. Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase. J. Med. Chem. 2003, 46, 4702-4713.
64. Fujita, M.; Hirayama, T.; Ikeda, N. Design, synthesis and bioactivities of novel diarylthiophenes: inhibitors of turnor necrosis factor-alpha(TNF-alpha) production. Bioorg. Med. Chem. Leu. 2002, 10, 3113-3122.
65. Natarajan, S.R.; Wisnoski, D.D.; Singh, S.B.; Stelmach, J.E.; O'Neill, E.A.; Schwartz, C.D.; Thompson, C.M.; Fitzgerald, C.E.; O'Keefe, S.J.; Kumar, S.; Hop, C.E.C.A.; Zaller, D.M.; Schmatz, D.M.; Doherty, J.B. p38 MAP kinase inhibitors. part 1: design and developmentof a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg. Med. Chem. Lett. 2003, 13, 273 -276.
66. Schlapbach, A.; Heng, R.; Di, P.F. A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 357-360.
67. Stelmach, J.E.; Liu, L.; Patel, S.B.; Pivnichny, J.V.; Scapin, G.; Singh, S.; Hop, C.E.C.A.; Wang, Z.; Strauss, JR.; Cameron, P.M.; Nichols,E.A.; O'Keefle, S.J.; O'Neill, E.A.; Schmatz, D.M.; Schwartz,C.D.; Thompson, C.M.; Zaller, D.M.; Doherty, J.B. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p3 8 MAP kinase. Bioorg. Med. Chem. Lett. 2003, 13, 277-280.
68. Hunt, J.A.; Kallashi, F.; Ruzek, R.D.; Sinclair, P.J.; Ita, I.; McCormick, S.X.; Pivnichny, J.V.; Hop, C.E.C.A.; Kumar, S.; Wang, Z.; O'Keefe, S.J.; O'Neill, E.A.; Porter, G.; Thompson, J.E.; Woods, A.; Zaller, D.M.; Doherty, J.B. p38 Inhibitors: piperidine-and 4-aminopiperidine-substitated naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorg. Med. Chem. Lett. 2003, 13, 467-470.
69. Fitzgerald, C.E.; Patel, S.B.; Becker, J.W.; Cameron, P.M.; Zaller, D.; Pikounis, V.B.; O'Keefe, S.J.; Scapin, G. Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 2003, 10, 764-769.
70. Colletti, S.L.; Frie, J.L.; Dixon, E.C.; Singh, S.B.; Choi, B.K.; Scapin, G.; Fitzgerald, C.E.; Kumar, S.; Nichols, E.A.; O'Keefe, S.J.; O'Neill, E.A.; Porter, G.; Samuel, K.; Schmatz, D.M.; Schwartz, C.D.; Shoop, W.L.; Thompson, C.M.; Thompson, J.E.; Wang, R.; Woods, A.; Zaller, D.M.; Doherty, J.B. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones. J. Med. Chem. 2003,46,349-352.
71. Wan. Z.; Boehm, J.C.; Bower, M.J.; Kassis, S.; Lee, J.C.; Zhao, B.; Adams, J.L. N-Phenyl-N-purin-6-yl ureas: The design and synthesis of p38.alpha. MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2003,13,1191-1194.
72. Goldstein, D.M.; Labadie, S.S.; Rotstein, D.M.; Sjogren, E.B.; Talamas, F.X. Preparation of 5-amino-4-aroyl-1-arylpyrazoles as p38 MAP kinase inhibitors. Edited by (F.Hoffmann-La Roche A.-G. S. 2000-EP8981[2001021591], 112. 2001. WO. 14-9-2000. Ref Type: Patent
73. Ottosen, E.R.; Sorensen, M.D.; Bjoerkling, F.; Skak-Nielsen, T.; Fjording, M.S.; Aaes, H.; Binderup, L. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med. Chem. 2003, 46, 5651-5662.
74. Brown, D.S.; Belfield, A.J.; Brown, G.R.; Campbell, D.; Foubister, A.; Masters, D.J.; Pike, K.G.; Snelson, W.L.; Wells, S.L. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 2004, 14, 5383- 5387.
75. Cumming, J.G.; McKenzie, C.L.; Bowden, S.G.; Campbell, D.; Masters, D.J.; Breed, J.; Jewsbury, P.J. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bloorg. Med. Chem. Lett. 2004, 14, 5389-5394.
76. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L.F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43,133-138.
77. Leftheris, K.; Ahmed, G.; Chan, R.; Dyckman, A.J.; Hussain, Z.; Ho, K.; Hynes, J. Jr.; Letourneau, J.; Li, W.; Lin, S.; Metzger, A.; Moriarty, K.J.; Riviello, C.; Shimshock, Y.; Wen, J.; Wityak, J.; Wrobleski, S.T.; Wu, H.; Wu, J.; Desai, M.; Gillooly, K.M.; Lin, T.H.; Loo, D.; McIntyre, K.W.; Pitt, S.; Shen, D.R.; Shuster, D.J; Zhang, R.; Diller, D.; Doweyko, A; Sack, J.; Baldwin, J.; Barrish, J.; Dodd, J.; Henderson, I.; Kanner, S.; Schieven, G.L.; Webb, M. The discovery of orally active triaminotriazine aniline amides as inhibitors ofp38 MAP kinase. J. Med. Chem. 2004, 47, 6283-6291.
78. Salituro, F.; Galullo, V.; Bellon, S.; Bemis, G.; Cochran, J. Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase. Edited by (Vertex Pharmaceuticals Incorporated U. 99-US10291[9958502], 99. 1999. WO. 11-5-1999. Ref Type: Patent
79. Salituro, F.G.; Bemis, G. Preparation of urea derivatives as inhibitors of p38. Edited by (Vertex Pharmaceuticals Incorporated U. 98-US13496[9900357], 93. 1999. WO. 29-6-1998. Ref Type: Patent
80. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M.K.; Lee, W.; Lowinger, T.B.; Redman, A.M.; Johnson, J.S.; Kingery-Wood, J.; Scott, W.J. Discovery of a new class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2047-2050.
81. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A.G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate. J. Med. Chem. 2002, 45, 2994-3008.
82. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Grob, P.M.; Hickey, E.R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268-272.
83. Regan, J.; Capolino, A.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Hickey, E.; Kroe, R.R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C.A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-Activity Relationships of the p38.alpha. MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl) -3-[4-(2-morpholin-4-yl-ethoxy) naph- thalen-1-yl]urea (BIRB 796). J. Med. Chem. 2003, 46, 4676-4686.
84. Regan, J.; Pargellis, C.A.; Cirillo, P.F.; Gilmore, T.; Hickey, E.R.; Peet, G.W.; Proto, A.; Swinamer, A.; Moss, N. The kinetics of binding to p38 MAP kinase by analogues of BIRB 796. Bioorg. Med Chem. Lett. 2003, 13, 3101-3104.
85. Redman, A.M.; Johnson, J.S.; Daily, R.; Swartz, S.; Wild, H.; Paulsen, H.; Caringal, Y.; Gunn, D.; Renick, J.; Osterhout, M.; Kingery-Wood, J.; Smith, R.A.; Lee, W.; Dumas, J.; Wilhelm, S.M.; Housley, T.J.; Bhargava, A.; Ranges, G.E.; Shrikbande, A.; Young, D.; Bombara, M.; Scott, W.J. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas. Bioorg. Med. Chem. Lett. 2001, 11, 9-12.
86. Dumas, J.; Hatoum-Mokdad, H.; Sibley, R.; Riedl, B.; Scott, W.J.; Monahan, M.K.; Lowinger, T.B.; Brennan, C.; Natero, R.; Turner, T. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000,10, 2051-2054.
87. Dumas, J.; Hatoum-Mokdad, H.; Sibley, R.N.; Smith, R.A.; Scott, W.J.; Khire, U.; Lee, W.; Wood, J.; Wolanin, D.; Cooley, J.; Bankston, D.; Redman, A.M.; Schoenleber, R.; Caringal, Y.; Gunn, D.; Romero, R.; Osterhout, M.; Paulsen, H.; Housley, T.J.; Wilhelm, S.M.; Pirro, J.; Chien, D.S.; Ranges, G.E.; Shrikhande, A.; Muzsi, A.; Bortolon, E.; Wakefield, J.; Gianpaolo Ostravage, C.; Bhargava, A.; Chau, T. Synthesis and pharmacological characterization of a potent; orally active p38 kinase inhibitor. Bioorg. Med Chem. Lett. 2002, 1Z 1559-1562.
88. Kroe, R.R.; Regan, J.; Proto, A.; Peet, G.W.; Roy, T.; Landro, L.D.; Fuschetto, N.G.; Pargellis, C.A.; Ingraham, R.H. Thermal Denaturation: A Method to Rank Slow Binding, High-Affinity P38a MAP Kinase Inhibitors. J Med. Chem. 2003, 46, 4669-4675.
89. Gill, A.L.; Frederickson, M.; Cleasby, A.; Woodhead, S.J.; Carr, M.G.; Woodhead, A.J.; Walker, M.T.; Congreve, M.S.; Devine, L.A.; Tisi, D.; O'Reilly, M.; Seavers, L.C.; Davis, D.J.; Curry, J.; Anthony, R.; Padova, A.; Murray, CW.; Carr, R.A.; Jhoti, H. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 2005, 48, 414-426.
90. Dominguez, C.; Powers, D.A. and Tamayo, N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr. Opin. Drug Discov. Develop. 2005,8, 421-430.
91. Moss, M.L.; An, S.L.; Milla, M.E.; Bickett, D.M.; Burkhart, W.; Carter, H.L.; Chen, W.J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; Hoffman, C.R.; Kost, T.A.; Lambert, M.H.; Leesnitzer, M.A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L.K.; Schoenen, F.; Seaton, T.; Su, J.L.; Becherer, J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997, 385, 733-736.
92. Thomberry, N.A.; Bull, H.G.; Calaycay, J.R.; Chapman, K.T.; Howard, A.D.; Kostura, M.J.; Miller, D.K.; Molineaux, S.M.; Weidner, J.R.; Aunins, J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992,356, 768-774.
93. Feige, U.; Hu, Y.L.; Gasser, J.; Campagnuolo, G.; Munyakazi, L.; Bolon, B. Anti-interleukin-I and anti-tumor necrosis factor-.alpha. synergistically inhibit adjuvant arthritis in Lewis rats. Cell. Mol. Life Sci. 2000, 57, 1457-1470.